Infertility Clinical Trial
Official title:
The Evaluation of a Preparatory Information Movie on Oocyte Aspiration: a Randomized Controlled Trial
The Preparatory information on Oocyte Aspiration Movie Randomized Controlled Trial (POAM-RCT) primarily aims to evaluate whether a new preparatory information on oocyte aspiration movie (POAM) decreases the anxiety of women on the day of their first oocyte aspiration for in vitro fertilisation (IVF). The control group of this RCT will receive care as usual. The intervention group will additional be given access to a preparatory information movie on oocyte aspiration 1-3 days before their oocyte aspiration via a secured link. Women's anxiety will be assessed with the 'State module of the State Trait Anxiety Inventory (STAI-state)' upon arrival at the fertility clinic on the day of the oocyte aspiration. At the same time other questionnaires will be administered. More specifically, men's anxiety and both partner's infertility specific distress will be assessed. In addition, to these secondary outcomes, clinical pregnancy with fetal heart beat and miscarriage will be followed-up 12 weeks after the oocyte aspiration. Finally, treatment delay and treatment discontinuation and long-term clinical outcomes (i.e. live birth from the first fresh embryo transfer, clinical pregnancy with fetal heart beat from the frozen embryo transfers of 1st IVF-cycle and the 12-months cumulative clinical pregnancy rates) will be followed-up twelve months after oocyte aspiration. This RCT will include 190 women (and their male partners) treated with a 1st cycle of IVF (with or without ICSI and PGD). Analysis will be according to intention to treat.
Title: The evaluation of a preparatory information movie on oocyte aspiration: a Randomized
Controlled Trial (POAM-RCT) Study purpose: To evaluate whether the preparatory information
movie on oocyte aspiration (POAM) decreases the anxiety of ART-couples on the day of their
first oocyte aspiration.
Primary outcome: The primary outcome is women's 'state anxiety', which will be assessed with
the reliable 'State Trait Anxiety Inventory, state module (STAI-state)' questionnaire upon
arrival at the fertility clinic on the day of the oocyte aspiration.
Secondary outcomes: Three secondary patient-reported outcomes will be assessed simultaneously
with the primary outcome, upon arrival at the fertility clinic for oocyte aspiration.
First, men's state anxiety will assessed with the STAI-state questionnaire. Second and third,
in both women and men, infertility-specific distress will be assessed.
The following two secondary clinical outcomes will be followed-up in all couples 12 weeks
after the oocyte aspiration: clinical pregnancy with fetal heart beat and miscarriage in case
of clinical pregnancy with fetal heart beat.
Other outcomes: As a follow-up the following will be extracted from the medical charts of
participating couples twelve months after the oocyte aspiration: long-term clinical outcomes
(i.e. live birth from the first fresh embryo transfer, clinical pregnancy with fetal heart
beat from the frozen embryo transfers of 1st IVF-cycle and the 12-months cumulative clinical
pregnancy rates) and long-term discontinuation parameters (i.e. censored by their medical
doctor to discontinue, IVF-delay or number of untreated cycles within 12 months and
IVF-discontinuation or whether or not start a 2nd IVF-cycle was started within 12 months).
Study design: Randomized controlled trial Sample size: 190 couples will be randomized to the
intervention or control group Summary of eligibility criteria: Inclusion criteria: Couples
treated with a 1st cycle of ART (IVF or ICSI; with or without PGD). Couples with a genetic
indication for PGD can be included as they are an important patient group and are as likely
as infertile patients to experience anxiety when they first come for oocyte retrieval.
Exclusion criterion: Couples going through a subsequent cycle of ART are not eligible as they
are not treatment naïve, but already know, from their first cycle, what will happen on the
day of oocyte aspiration.
Maximum duration of treatment of a subject: Each couple will participate from their
ART-intake until the day of their first oocyte aspiration.
Couples will be asked for informed consent during their ART-intake (i.e. individual or group
session with midwife; 1-3 months prior to oocyte aspiration) and will then be randomized to
either the intervention group or the control group.
Participating couples of the intervention group will receive care as usual and will watch the
preparatory information movie on oocyte aspiration (POAM) 1-3 days before their oocyte
aspiration. Their gynecologist or midwife will empower them to watch the movie when they call
them to plan the oocyte aspiration and will send them the secured link to the movie via
email.
Participating couples of the control group will receive care as usual (as will participating
couples of the intervention group) and will not get access to the preparatory information
movie on oocyte aspiration (POAM).
When they arrive at the fertility clinic on the day of oocyte aspiration both partners of
participating couples of the intervention and control group will be asked to fill out a
questionnaire (5-10 minutes) before any clinical procedures are performed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A |